NCT03486626

Endometrial Thickness and Subendometrial Vascularity in Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin

Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 85 (actual)
• Sponsor: Ain Shams Maternity Hospital · Academic / Other
• Sex: Female
• Age: 20 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The participants will receive metformin 500mg 3times per day for 3months and one month is left for spontaneous pregnancy to occur or not (primary outcome ) and the investigators will check endometrial thickness and subendometerial vascularity as markers of endometrial receptivity before and after the treatment.

Conditions

• Polycystic Ovary Syndrome
• Anovulatory

Interventions

Type	Name	Description
DRUG	Metformin	Metformin to increase pregnancy rate in polycystic ovarian syndrome patients

Timeline

• Start date: 2018-01-02
• Primary completion: 2018-09-01
• Completion: 2018-10-01
• First posted: 2018-04-03
• Last updated: 2018-06-26

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated drug study